HK1208057A1 - Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression - Google Patents

Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression Download PDF

Info

Publication number
HK1208057A1
HK1208057A1 HK15108666.9A HK15108666A HK1208057A1 HK 1208057 A1 HK1208057 A1 HK 1208057A1 HK 15108666 A HK15108666 A HK 15108666A HK 1208057 A1 HK1208057 A1 HK 1208057A1
Authority
HK
Hong Kong
Prior art keywords
prediction
gene expression
response
breast cancer
progesterone receptor
Prior art date
Application number
HK15108666.9A
Other languages
English (en)
Chinese (zh)
Inventor
Carol LANGE
Todd Philip Knutson
Jason Basil NIKAS
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of HK1208057A1 publication Critical patent/HK1208057A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15108666.9A 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression HK1208057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639407P 2012-04-27 2012-04-27
US201261639407P 2012-04-27
PCT/US2013/032677 WO2013162776A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Publications (1)

Publication Number Publication Date
HK1208057A1 true HK1208057A1 (en) 2016-02-19

Family

ID=48045769

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108666.9A HK1208057A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression

Country Status (14)

Country Link
US (1) US10501800B2 (enExample)
EP (1) EP2841594A1 (enExample)
JP (1) JP2015516155A (enExample)
KR (1) KR20150028232A (enExample)
AU (1) AU2013252913A1 (enExample)
CA (1) CA2871590A1 (enExample)
HK (1) HK1208057A1 (enExample)
IL (1) IL235351A0 (enExample)
MX (1) MX2014013044A (enExample)
NZ (1) NZ701652A (enExample)
PH (1) PH12014502410A1 (enExample)
RU (1) RU2014147625A (enExample)
WO (1) WO2013162776A1 (enExample)
ZA (1) ZA201407853B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1208057A1 (en) 2012-04-27 2016-02-19 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
US20140363425A1 (en) * 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US20150276767A1 (en) * 2014-03-12 2015-10-01 The University Of Sydney Systems and methods for identifying cancers having activated progesterone receptors
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US10942183B2 (en) 2017-04-05 2021-03-09 Regents Of The University Of Minnesota Methods of detecting progesterone receptor and of detecting an expression level
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
JP2023518424A (ja) * 2020-03-17 2023-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム
JP7619556B2 (ja) * 2020-10-08 2025-01-22 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
US20250005743A1 (en) * 2023-06-30 2025-01-02 Mackay Memorial Hospital Method and system for identifying hormone receptor status

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271579A1 (en) 2000-06-28 2002-01-08 University Technology Corporation Progesterone receptor-regulated gene expression and methods related thereto
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
HK1208057A1 (en) 2012-04-27 2016-02-19 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression

Also Published As

Publication number Publication date
IL235351A0 (en) 2014-12-31
JP2015516155A (ja) 2015-06-11
KR20150028232A (ko) 2015-03-13
MX2014013044A (es) 2015-06-23
US10501800B2 (en) 2019-12-10
WO2013162776A1 (en) 2013-10-31
RU2014147625A (ru) 2016-06-20
CA2871590A1 (en) 2013-10-31
ZA201407853B (en) 2015-12-23
PH12014502410A1 (en) 2015-01-12
AU2013252913A1 (en) 2014-11-27
NZ701652A (en) 2016-09-30
EP2841594A1 (en) 2015-03-04
US20130316992A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
MX2015018051A (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
PH12013500544A1 (en) Breast cancer diagnostics
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
WO2011085276A3 (en) Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
IN2014DN08312A (enExample)